10-QPeriod: Q1 FY2012

INTUITIVE SURGICAL INC Quarterly Report for Q1 Ended Mar 31, 2012

Filed April 19, 2012For Securities:ISRG

Summary

Intuitive Surgical, Inc. (ISRG) demonstrated strong financial performance in the first quarter of 2012, reporting a significant increase in total revenue to $495.2 million, up 28% year-over-year. This growth was primarily driven by robust demand for its da Vinci Surgical Systems and a notable increase in recurring revenue from instruments, accessories, and services, which now constitute 58% of total revenue. The company successfully expanded its installed base of da Vinci systems and saw a healthy rise in the number of procedures performed, indicating continued market adoption and patient value. Profitability also saw a significant improvement, with net income rising to $143.5 million, a 38% increase from the prior year period, leading to a diluted EPS of $3.50, up from $2.59. The company's financial position remains strong, with substantial cash and investments totaling $2.4 billion. Despite ongoing European economic uncertainties affecting capital sales in that region, ISRG's overall performance highlights strong operational execution and continued market leadership in robotic-assisted surgery.

Financial Highlights

45 data points
Beta

Revenue

$495.20M

71.9% Gross Margin

Net Income

$143.50M

29.0% Net Margin

EPS (Diluted)

$0.39

Total Assets

$3.33B

Cash & Equivalents

$325.90M

Free Cash Flow

$165.00M

Financial Statements
Beta
Revenue$495.20M
Cost of Revenue$139.30M
Gross Profit$355.90M
R&D Expenses$38.40M
SG&A Expenses$124.20M
Operating Expenses$162.60M
Operating Income$193.30M
Net Income$143.50M
EPS (Basic)$0.40
EPS (Diluted)$0.39
Shares Outstanding (Basic)355.50M
Shares Outstanding (Diluted)369.00M

Key Highlights

  • 1Total revenue grew 28% to $495.2 million in Q1 2012, driven by strong system sales and procedure growth.
  • 2Recurring revenue increased 31% to $288.6 million, representing 58% of total revenue, indicating increasing customer reliance on instruments, accessories, and services.
  • 3Net income rose 38% to $143.5 million, with diluted EPS of $3.50, up from $2.59 in the prior year quarter.
  • 4The installed base of da Vinci Surgical Systems grew to 2,226 units by March 31, 2012.
  • 5da Vinci procedures performed increased by approximately 29% year-over-year.
  • 6The company reported strong cash flow from operations ($166.5 million) and maintained a healthy cash and investment balance of $2.4 billion.
  • 7Gross profit margin remained strong at 72% for the quarter, demonstrating effective cost management despite new product introductions.

Frequently Asked Questions

Intuitive Surgical's revenue growth is primarily driven by the continued adoption and utilization of its da Vinci Surgical Systems. This includes both the initial capital sales of the systems and, increasingly, the recurring revenue generated from the sale of instruments, accessories, and service contracts needed for ongoing procedures. The increasing number of da Vinci procedures performed globally is a key indicator of this adoption.

The company is effectively managing its expenses, with operating expenses growing at a slightly slower pace than revenue, leading to a 30% increase in operating income. Gross profit margins remain strong at 72%. While R&D and SG&A expenses have increased to support growth and new product development, the company is maintaining healthy profitability, with net income increasing by 38% year-over-year. The effective tax rate also decreased due to a favorable IRS guidance update.

Intuitive Surgical maintains a very strong financial position. As of March 31, 2012, the company had approximately $2.4 billion in cash, cash equivalents, and investments. Cash flow from operations remains robust, providing ample liquidity to fund ongoing operations, investments in R&D, and potential future growth initiatives. The company expects to continue funding its growth through operational cash flows.

The report mentions two ongoing class-action lawsuits and derivative lawsuits related to past alleged misstatements. While the company believes it has meritorious defenses and that these cases are unlikely to have a material adverse effect on its business, financial position, or results of operations, it is unable to reasonably estimate the ultimate outcome at this time. No amounts have been accrued related to these cases.